Literature DB >> 7857586

Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

A Wolkin1, E Duncan, M Sanfilipo, S Wieland, T B Cooper, J Rotrosen.   

Abstract

The purpose of this study was to evaluate the hypothesis that neuroleptic non-response in the face of "adequate" DA post-synaptic receptor blockade reflects failure of regulatory mechanisms to decrease DA pre-synaptic activity. Eight chronic schizophrenics, meeting rigorous criteria for neuroleptic non-response, were treated for four weeks with alpha-methylparatyrosine as an adjunct to their previously stable neuroleptic dose. Treatment with AMPT produced a prompt decrease in plasma HVA that was, on average, 72% lower at the end of the study. While there was also strong clinical evidence of reduction in central dopaminergic activity (both a significant reduction in dyskinetic movements and increase in extrapyramidal symptoms), there was virtually no change in severity of psychotic symptoms. Thus, in this group of non-responders, psychotic symptoms persisted despite both extensive dopamine post-synaptic receptor blockade and marked reduction of presynaptic activity. These symptoms may not be directly DA dependent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7857586     DOI: 10.1007/bf01283030

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  45 in total

1.  Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons.

Authors:  J R Hollerman; E D Abercrombie; A A Grace
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

2.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

4.  Plasma homovanillic acid as a predictor of response to neuroleptics.

Authors:  R Davila; E Manero; M Zumarraga; I Andia; J W Schweitzer; A J Friedhoff
Journal:  Arch Gen Psychiatry       Date:  1988-06

5.  Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.

Authors:  J Wålinder; A Skott; A Carlsson; B E Roos
Journal:  Arch Gen Psychiatry       Date:  1976-04

6.  The effects of diet and physical activity on plasma homovanillic acid in normal human subjects.

Authors:  K S Kendler; R C Mohs; K L Davis
Journal:  Psychiatry Res       Date:  1983-03       Impact factor: 3.222

7.  Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat.

Authors:  F J White; R Y Wang
Journal:  Life Sci       Date:  1983-02-28       Impact factor: 5.037

8.  Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools.

Authors:  M Larsson; R Ohman; L Wallin; J Wålinder; A Carlsson
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

9.  Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.

Authors:  M Davidson; M F Losonczy; R C Mohs; J C Lesser; P Powchik; L B Freed; B M Davis; V V Mykytyn; K L Davis
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

10.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

Authors:  L Farde; F A Wiesel; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1988-01
View more
  2 in total

Review 1.  Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide.

Authors:  Abdulla Badawy
Journal:  Psychopharmacology (Berl)       Date:  2013-07-05       Impact factor: 4.530

2.  Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.

Authors:  Elias Mouchlianitis; Michael A P Bloomfield; Vincent Law; Katherine Beck; Sudhakar Selvaraj; Naresh Rasquinha; Adam Waldman; Federico E Turkheimer; Alice Egerton; James Stone; Oliver D Howes
Journal:  Schizophr Bull       Date:  2015-12-17       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.